Lumos Diagnostics Holdings Ltd.ASX: LDX

Lumos Announces FebriDx CLIA Waiver Application Submission

· Issued by Lumos Diagnostics Holdings Ltd.

Filed with ASX · · 3 pages · English

Summary by 6ix AI

Lumos Diagnostics Holdings Ltd. has submitted its application for a CLIA waiver to the U.S. FDA for its product FebriDx, which helps differentiate between bacterial and non-bacterial infections. The clinical trial data for FebriDx exceeded performance targets, demonstrating high concordance rates between trained and untrained operators. This submission triggers milestone payments from BARDA and a prepayment from PHASE Scientific, significantly expanding Lumos's market opportunity in the U.S. The company expects FDA feedback by the end of the first quarter of the following calendar year.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Lumos Diagnostics Holdings Ltd. on 6ix

Earlier from Lumos Diagnostics

Later from Lumos Diagnostics

All Lumos Diagnostics news releases